Regarding overall CV risk, GLP1 RA—and in particular liraglutide, semaglutide, dulaglutide, and albiglutide—were able to significantly reduce MACE in the high-CV-risk T2D population, in comparison to placebo [55,81,89]. This evidence concerns the gene GCG and type 2 diabetes mellitus.